Cefiderocol for Extensively Drug-Resistant Gram-Negative Bacterial Infections: Real-world Experience From a Case Series and Review of the Literature

Open Forum Infect Dis. 2020 May 21;7(6):ofaa185. doi: 10.1093/ofid/ofaa185. eCollection 2020 Jun.

Abstract

Cefiderocol is a new siderophore cephalosporin with activity against carbapenem-resistant gram-negative bacteria. Data on its clinical efficacy are limited to complicated urinary tract infections. We present a series of 3 patients successfully treated with cefiderocol for complicated health care-associated infections and review published case reports.

Keywords: carbapenemase; case series; cefiderocol; drug-resistant gram-negatives; review.